DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Safety and Efficacy of Brimonidine in Patients With Glaucoma or Ocular Hypertension

Information source: Allergan
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Glaucoma; Ocular Hypertension

Intervention: brimonidine (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Allergan


This Study will evaluate the safety and efficacy of brimonidine in patients with glaucoma or ocular hypertension

Clinical Details

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Primary outcome: lowering of intraocular pressure


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- ocular hypertension or glaucoma in both eyes

- currently treated with brimonidine

- requires IOP-lowering therapy in both eyes

Exclusion Criteria:

- uncontrolled systemic disease

- known allergy or sensitivity to brimonidine

Locations and Contacts

Additional Information

Link to Clinical Trial Results

Starting date: January 2005
Last updated: May 27, 2011

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017